1 North Waukegan Road
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.
Stock Symbol: ABBV
Stock Exchange: NYSE
We’re a company that takes on the toughest health challenges. But we do more than treat diseases—we aim to make a remarkable impact on people’s lives. We are AbbVie, a highly focused research-driven biopharmaceutical company.
1559 articles with AbbVie
AbbVie to Showcase Migraine Portfolio and Pipeline During the 16th European Headache Federation Congress
AbbVie announced that data from its robust migraine portfolio will be presented at the 16th European Headache Federation Congress 2022 taking place in Vienna, Austria, December 7-10.
AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline
AbbVie and HotSpot Therapeutics, Inc. today announced an exclusive worldwide collaboration and option to license agreement for HotSpot's discovery-stage IRF5 program for the treatment of autoimmune diseases.
AbbVie (NYSE: ABBV) will participate in the 5th Annual Evercore ISI Virtual HealthCONx Conference on Tuesday, November 29, 2022.
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Moderate to Severe Active Crohn's Disease
AbbVie announced the European Commission approved SKYRIZI® as the first specific interleukin-23 inhibitor for the treatment of adults with moderately to severely active Crohn's disease who have had inadequate response, lost response or were intolerant to conventional or biologic therapy.1,2,3
AbbVie Highlights Blood Cancer Data From Its Growing Oncology Pipeline at the 64th ASH Annual Meeting
AbbVie (NYSE: ABBV) will present results from nearly 65 company and partner abstracts across 8 types of cancer during the upcoming American Society of Hematology (ASH) annual meeting (December 10-13) in New Orleans, Louisiana.
AbbVie will participate in the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022.
U.S. FDA Accepts for Priority Review the Biologics License Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma
The application is supported by data from EPCORE™ NHL-1 Phase 1/2 trial evaluating the safety and preliminary efficacy of subcutaneous epcoritamab in patients with relapsed, progressive or refractory CD20+ mature B-cell non-Hodgkin's lymphoma, including large B-cell lymphoma.
BioSpace's 2023 “Best Places to Work,” highlights innovative companies with a positive workplace culture, flexibility and strong leadership.
AbbVie will participate in the 4th Annual Wolfe Research Healthcare Conference on Tuesday, November 15, 2022.
AbbVie Presents Data from Extensive Portfolio at the American College of Rheumatology Convergence 2022
AbbVie (NYSE: ABBV) today announced it would present new data across its rheumatology portfolio, including RINVOQ® (upadacitinib) for rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis, and SKYRIZI® (risankizumab) for psoriasis and psoriatic arthritis at the American College of Rheumatology's annual meeting (ACR Convergence 2022).
AbbVie's investigational neurotoxin, designed to prevent postoperative atrial fibrillation, missed the primary endpoint in a Phase II trial, the company announced Monday.
AbbVie Announces Late-Breaking Results from Phase 2 Exploratory NOVA Trial of Novel Investigational Neurotoxin AGN-151607 for the Prevention of Postoperative Atrial Fibrillation in Cardiac Surgery Patients
AbbVie (NYSE: ABBV) today announced new results from its exploratory NOVA phase 2 dose-ranging study evaluating the efficacy and safety of AGN-151607, a novel investigational neurotoxin for the prevention of postoperative atrial fibrillation (POAF) in cardiac surgery patients.
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is inviting people across the country to take a "Moment for You" on Wednesday, November 16 and celebrate the biggest event of the year for BOTOX® Cosmetic.
Inventiva announced that AbbVie communicated during their third-quarter financial results on Friday October 28th, that they decided to stop the development of cedirogant, an oral RORg inverse agonist jointly discovered by Inventiva and AbbVie for the treatment of autoimmune diseases, following the analysis of a recently concluded nonclinical toxicology study.
While reporting stellar third-quarter financials, AbbVie announced it was halting development of cedirogant and provided updates on Skyrizi, Rinvoq and Humira.
AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2022.
AbbVie Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Large B-Cell Lymphoma (LBCL)
European Medicines Agency (EMA) validates AbbVie's Marketing Authorization Application.
AbbVie to Present Data from Extensive Portfolio at American College of Gastroenterology Annual Scientific Meeting
AbbVie (NYSE: ABBV) today announced that 26 abstracts across its gastroenterology portfolio will be presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting, October 21-26, 2022, in Charlotte, N.C., and virtually.
AbbVie (NYSE: ABBV) today announces that the U.S. Food and Drug Administration (FDA) has approved RINVOQ®.
AbbVie is buying DJS Antibodies for $225 million in cash to gain access to the British company’s potential fibrotic diseases drug and antibody discovery program.